OBJECTIVE: To assess the extent to which quantitative clinical measurement is performed by rheumatologists in the longitudinal followup of patients with rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and fibromyalgia (FM) in routine outpatient practice in Canada. METHODS: A cross sectional postal survey was conducted using an 18 item self-administered questionnaire sent to Canadian Rheumatology Association members. RESULTS: Rheumatologists (response rate 85%) were more likely to longitudinally follow patients with RA and AS than those with OA or FM. There was a high degree of variability in the methods used to monitor patients longitudinally. Many measures used in clinical research were used infrequently in routine clinical practice. In general, the major health status measures surveyed were not used in clinical monitoring. There was a high level of agreement (>80%) that the characteristics required of an outcome measure for use in clinical practice should include simplicity, brevity, ease of scoring, reliability, validity, and sensitivity to change. CONCLUSION: The majority of Canadian rheumatologists perform outcome measurement during the longitudinal followup of their outpatients with RA, AS, OA, and FM. However, the process lacks standardization. High performance health status measures, developed for clinical research, have not been widely adopted in rheumatology practices. There is agreement on the characteristics required by Canadian rheumatologists for measurement procedures used in routine clinical care. Quantitative measurement in clinical practice using standardized procedures is an attainable, but as yet, unrealized opportunity.
OBJECTIVE: To assess the extent to which quantitative clinical measurement is performed by rheumatologists in the longitudinal followup of patients with rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and fibromyalgia (FM) in routine outpatient practice in Canada. METHODS: A cross sectional postal survey was conducted using an 18 item self-administered questionnaire sent to Canadian Rheumatology Association members. RESULTS: Rheumatologists (response rate 85%) were more likely to longitudinally follow patients with RA and AS than those with OA or FM. There was a high degree of variability in the methods used to monitor patients longitudinally. Many measures used in clinical research were used infrequently in routine clinical practice. In general, the major health status measures surveyed were not used in clinical monitoring. There was a high level of agreement (>80%) that the characteristics required of an outcome measure for use in clinical practice should include simplicity, brevity, ease of scoring, reliability, validity, and sensitivity to change. CONCLUSION: The majority of Canadian rheumatologists perform outcome measurement during the longitudinal followup of their outpatients with RA, AS, OA, and FM. However, the process lacks standardization. High performance health status measures, developed for clinical research, have not been widely adopted in rheumatology practices. There is agreement on the characteristics required by Canadian rheumatologists for measurement procedures used in routine clinical care. Quantitative measurement in clinical practice using standardized procedures is an attainable, but as yet, unrealized opportunity.
Authors: Kirstie L Haywood; Andrew M Garratt; Sandra Carrivick; Joanne Mangnall; Suzanne M Skevington Journal: Qual Life Res Date: 2009-03-07 Impact factor: 4.147
Authors: N Bellamy; C Anjema; T Chhina; N Dudek; B Hurley; B Landesman; L Probyn; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: P Ravaud; B Giraudeau; I Logeart; J S Larguier; D Rolland; R Treves; L Euller-Ziegler; B Bannwarth; M Dougados Journal: Ann Rheum Dis Date: 2004-06 Impact factor: 19.103
Authors: Ana Lledó Boyer; Maria Angeles Mira Pastor; Nieves Pons Calatayud; Sofía Lopez-Roig; Maria Carmen Cantero Terol Journal: Rheumatol Int Date: 2008-12-19 Impact factor: 2.631
Authors: N Bellamy; C Anjema; N Alikhan; T Chhina; D Dhanoa; D Edelist; Z Esufali; F Ismail; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: N Bellamy; C Anjema; T S Frankovic; N Horowitz; G C Mills; S Shulman; C Smith; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: N Bellamy; C Anjema; D Dhanoa; A Joglekar; G C Mills; G Nesrallah; C Smith; C Ucar; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473